Grant List
Represents Grant table in the DB
GET /v1/grants?sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=program_officials", "prev": null }, "data": [ { "type": "Grant", "id": "10583", "attributes": { "award_id": "1U01CK000675-01", "title": "TRANSMIT: Training Research Acumen iN Students Modeling Infectious Threats", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 297120, "principal_investigator": { "id": 26605, "first_name": "Frederick R.", "last_name": "Adler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26606, "first_name": "Lindsay T.", "last_name": "Keegan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26607, "first_name": "DAMON", "last_name": "TOTH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 26608, "first_name": "YUE", "last_name": "ZHANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "The ongoing COVID-19 pandemic has overwhelmed healthcare and public health systems, underscoring the need to anticipate disease outbreaks and prepare resources such as hospital beds and staff. One cost-effective and timely way to prepare resources to respond to these outbreaks is through the use of mathematical modeling. Models can act as a virtual laboratory to explore a variety of scenarios, interventions, or applications in a timely manner to inform policy interventions. While the COVID-19 pandemic highlighted the gaps that models can fill, it also highlighted a considerable gap in modeling: there is a lack of modeling professionals trained in developing and applying transmission models to healthcare settings. In this proposal, we detail three projects aimed to train three predoctoral fellows in different aspects of mathematical modeling of healthcare associated pathogens. These projects tackle different pathogens and components of disease transmission in a healthcare setting; and, while each project is distinct, they dovetail nicely, resulting in a cohesive research program. Project 1 tackles a critical component of disease transmission in healthcare settings: COVID-19 in long-term care facilities (LTCFs). Throughout the pandemic, LTCFs bore a disproportionate burden of mortality. Yet, while it is clear that LTCFs important with regards to disease outcomes, whether or not they exert selective forces on SARS-CoV-2 that have shaped global patterns of pathogen evolution is not yet known. Here, we will develop models to quantify the phylogenetic relationships between community and long-term care facility lineages to understand the viral diversification attributable to healthcare settings. Project 2 explores the risk factors of patients hospitalized with SARS-CoV-2 for acquiring multi-drug resistant organisms (MDROs). The rapid spread of SARS-CoV-2 has changed to hospital infection control and antimicrobial stewardship policies. One such change has been widespread potentially unnecessary antibiotic use among hospitalized patients. Here, we will identify the characteristics of the sub-population disproportionately impacted by co-infections with MDROs for patients hospitalized with SARS- CoV-2. Project 3 integrates with both Project 1 and 2, to explore the evolution of antibiotic resistance due to variable dose and off-target antibiotic use in healthcare settings. Patients in hospitals and residents of LTCFs are exposed to a wide range of pathogens and treatments, and many of these organisms have themselves been exposed to a wide range of environmental antibiotics. Here, we will develop models of evolution to investigate the conditions that lead to the most intractable infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10615", "attributes": { "award_id": "1U01IP001180-01", "title": "RFA-IP-22-004, Platform to Assess Influenza and COVID-19 Vaccine Effectiveness in Underserved Arizona Populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 2500000, "principal_investigator": { "id": 26657, "first_name": "Vel", "last_name": "Murugan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 912, "ror": "", "name": "ARIZONA STATE UNIVERSITY-TEMPE CAMPUS", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Component A – Abstract: Annual influenza vaccination is the primary prevention strategy for infection and severe disease. A constantly evolving influenza virus through antigenic drift dictates that vaccines are re-evaluated every year. COVID-19 has overlapping symptoms with influenza and has significantly complicated the healthcare burden associated with viral infections, morbidity, and mortality. While COVID-19 vaccines received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA), additional COVID-19 vaccines are under development due to emerging variants, some of which are known to evade currently authorized vaccines. As such, boosters are recommended to thwart spikes and new waves of variant infections which complicates assessment of the effectiveness of both COVID-19 and seasonal influenza vaccines simultaneously. Phoenix, Arizona is the fifth largest and fastest growing city in the nation, and, importantly, is home to an ethnically and socioeconomically diverse population. Twice during the COVID-19 pandemic, Arizona was #1 worldwide in per capita COVID-19 cases. Arizona has seen a mixed adoption of vaccine use for both COVID-19 and influenza, allowing for excellent local comparisons. In this project, leveraging Arizona State University’s (ASU) core capabilities, we propose to study vaccine effectiveness (VE) in a diverse demographic and clinical population (including immunocompromised HIV patients) seen at outpatient clinics managed by ValleyWise Community Hospital, Phoenix Children’s Hospital and ASU Student Health Services. Given identified health disparities in infection and vaccination, we propose to examine social determinants of health to identify the most vulnerable groups. We will collect specimens (nasopharyngeal and/or anterior nasal swabs) and relevant demographic and clinical data from laboratory-confirmed cases of influenza and COVID-19 in children and adults with acute respiratory infection, seeking care in ambulatory clinics, to calculate vaccine effectiveness for both influenza and COVID- 19 vaccines. We will also sequence viral genomes to identify subtype/variants using our deep expertise and incomparable resources in next-generation sequencing and viral genomic bioinformatics. We will use this genomic sequencing data to further investigate VE analyses and understand virus evolution. Importantly, to examine health disparities in vaccination and vaccine effectiveness, we will implement longitudinal surveys and geographical information systems mapping to measure and model social determinants of health. Overall, our multidisciplinary program provides a comprehensive approach to study VE and to understand social determinates that drives health disparities. We believe the findings will have important, long lasting policy implications towards vaccination and examination of VE.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5124", "attributes": { "award_id": "NNX10AR42G", "title": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-01", "end_date": "2012-12-31", "award_amount": 0, "principal_investigator": { "id": 18257, "first_name": "DAVID", "last_name": "BUOTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1407, "ror": "", "name": "REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (6406)", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5113", "attributes": { "award_id": "1006919", "title": "Oklahoma Optical Initiative", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "EPSCoR Research Infrastructure" ], "program_reference_codes": [], "program_officials": [], "start_date": "2010-09-01", "end_date": "2013-08-31", "award_amount": 1176470, "principal_investigator": { "id": 18221, "first_name": "Henry", "last_name": "Neeman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 157, "ror": "", "name": "University of Oklahoma Norman Campus", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 18219, "first_name": "Dana", "last_name": "Brunson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 18220, "first_name": "James", "last_name": "Deaton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 157, "ror": "", "name": "University of Oklahoma Norman Campus", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "Oklahoma Optical Initiative \n\nProposal Number:\tEPS - 1006919 \nInstitution:\tUniversity of Oklahoma Norman Campus\nProject Director:\tHenry J. Neeman\n\nThis award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). \n\nThis OK Inter-campus and Intra-campus Cyber Connectivity (RII C2) project would be led by the University of Oklahoma Norman Campus to benefit the entire state.\n\nIntellectual Merit\nThrough the Oklahoma Optical Initiative (OOI), the OK RII C2 project plans to facilitate the ability to provision a substantial number of dedicated high performance connections, both within Oklahoma and to national and international networks (e.g., Internet2, NLR). OOI would transform Oklahoma's existing research ring from routed to optical, leveraging existing infrastructure while advancing optical switching components to a new level, facilitating substantial improvement in reliability, robustness, availability and potentially bandwidth, as well as enabling the ability to provision dedicated lambdas. This initiative will leverage extant and emerging investments by OneNet and University of Oklahoma (OU). \n\nIndividual Oklahoma institutions will achieve substantial connectivity transformations, so they can take advantage of OOI. In particular: \n(a) OU's supercomputer will have its world-facing network connectivity upgraded to 10 Gbps (10X increase);\n(b) OSU (Oklahoma State University) will be upgraded to 10 Gbps intra-campus (10x increase), from its current 1 Gbps intra-campus (but 10 Gbps ring-facing); \n(c) University of Tulsa will be upgraded to 1 Gbps (5X increase), for research use only, at no upcharge; \n(d) Langston University (LU) bandwidth for High Energy Physics (HEP) projects will be increased to 10 Gbps (100X increase), at no upcharge; \n(e) Noble bandwidth will be increased to 250 Mbps (5X increase) via a fiber Indefeasible Right to Use agreement, at no upcharge; \n(f) Rural and nonmetro connectivity will be improved, via redeploying extant optical components from the research ring to OneNet's remote hubsites. \n(g) The Oklahoma Telepresence Initiative will make High Definition telepresence available to all higher education campuses in Oklahoma.\n\nOklahoma currently has an RII Track 1 on bioenergy and an RII Track 2 on ecoinformatics. The Track 1, a collaboration among Oklahoma State University, the University of Oklahoma and the Samuel Roberts Noble Foundation (Noble), isn't a large consumer of network connectivity, but Noble currently is at only 45 Mbps, expected to be inadequate for emerging needs; the Track1 also includes the Oklahoma Cyberinfrastructure Initiative (OCII), which provides CI resources to 540 users at 24 institutions (including 11 of Oklahoma's 13 public universities), mostly without usage charges. The Track 2, a collaboration among OU, OSU, the University of Kansas and Kansas State University, uses substantial data, with constant collection and transformation of NASA data made available from a web portal. \n\nOther Data-Intensive Projects include: \n(a) Oklahoma has been a longstanding leader in meteorology research, especially in real time forecasting of severe storms, including: the Center for Analysis and Prediction of Storms; the Linked Environment for Atmospheric Discovery collaboration (NSF Large Information Technology Research); development of the Advanced Regional Prediction System as an NSF Science and Technology Center and now a key developer of the Weather Research and Forecasting (WRF) model; a just-awarded NSF Petascale Applications grant for Ensemble Kalman Filtering on the NSF's Blue Waters multi-petaflops system. \n(b) For the past 6 years, Oklahoma's DOE EPSCoR has supported a High Energy Physics collaboration among OU, OSU and LU, Oklahoma's only Historically Black University. In addition, OU and LU, with two other institutions, form the NSF-funded ATLAS Southwest Tier2 Center. At OU, HEP projects are expected to consume roughly 5 Gbps starting in 2010; at LU, campus networking capability is inadequate for LU's growing computing and data responsibilities. \n(c) The OU and OSU HPC centers support dozens of research teams. \n(d) The state's Science & Technology (S&T) plan includes bioenergy, plant science, weather and weather sensors, plus other areas that are supported under OCII but not called out in this RII C2 proposal.\n\nBroader Impacts\nThe Oklahoma Networking Mentorship Program will provide networking professionals from OU and OneNet to institutions across the state (20 institutions have expressed interest), to deliver presentations on the practicalities of the networking profession and job shadowing opportunities, both physical and virtual. In addition, each of the science projects described has its own extensive education program, Oklahoma Cyber-infrastructure Initiative (OCII) has its longstanding and successful SiPE education program, and Oklahoma EPSCoR has comprehensive educational and outreach programs, links to economic development and to initiatives designed to enhance public awareness of the importance of science.\n\nK-12 students and teachers are being exposed to cutting-edge science and CI through summer technology academies, mobile science vehicles, and teacher training workshops. Undergraduate student research experiences in industry and academia are supported and talented students are being recruited into bioenergy based graduate programs. Workshops are being geared towards the education, training and integration of CI in the outreach and research components of Oklahoma's RII projects. Conferences to encourage multidisciplinary, multi-campus collaborations and to enhance faculty competitiveness in future grant submissions are being supported. An entrepreneurial workshop, a business plan competition for students along with commercialization vouchers to assess the commercial potential of researcher's inventions would foster the spirit of entrepreneurship of both students and faculty. \n\nAlong with publications, website and wiki, outcomes of this RII C2 project are proposed to be disseminated via the Oklahoma Supercomputing Symposium, which in 8 years has had over 2000 attendees from 84 academic institutions in 23 states and Puerto Rico (32 in Oklahoma and 19 in 12 other EPSCoR jurisdictions), including PhD-, masters- and bachelors-granting universities, community colleges, career techs, a high school and public school systems, as well as 79 private companies, 29 government agencies (21 in Oklahoma) and 13 non-governmental organizations.\n\nRII education outreach initiatives embrace the inclusion of underrepresented groups and women, and strengthen competitiveness and diversity through collaboration with LU (Oklahoma's HBCU) and tribal college, facilitating transition from high school to college, providing culture-attuned counseling support, and promoting enhancement programs to retain students pursuing STEM disciplines. Other initiatives promote effective communication of scientific advances to enhance public awareness of the value of science to the state legislature and the general public. Collectively, the RII investments would position Oklahoma to enhance competitiveness for mainstream NSF funding.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10671", "attributes": { "award_id": "1U01IP001194-01", "title": "RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 987989, "principal_investigator": { "id": 26731, "first_name": "EMMANUEL B", "last_name": "WALTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "– Duke Human Vaccine Institute Duke University is pleased to respond to RFA-IP-22-004 entitled “US Platform to Measure the Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings” by submitting the application for Component B. Duke University will coordinate the activities of the Centers for Disease Control and Prevention’s Respiratory Virus Vaccine Effectiveness Network incorporating the collective breadth of scientific, program management, regulatory, data management, statistical, and information technology expertise of the Duke Human Vaccine Institute (DHVI). In particular, we will leverage our vast prior experience coordinating clinical investigations for both NIAID and the CDC to help facilitate the work of this project. The Duke Network Coordinating Center (NCC) will provide logistical and coordinating support by facilitating network communications through hosting video and in-person conferences, hosting a network SharePoint, providing reports and project updates and establishing a clear communication plan for network activities. As the NCC, The DHVI will help facilitate protocol development and establish standard operating procedures for network investigations. Studies will include evaluations of both influenza and SARS-CoV-2 vaccine effectiveness at preventing symptomatic respiratory infection in the community and household settings. As the NCC, the DHVI is also well poised to support network studies assessing vaccine immunogenicity in addition to studies using more complex virologic and immunologic influenza assays to detect influenza virus infection and the host immune response to infection. Working with the Duke University Health System IRB, the Duke NCC will provide the regulatory support to facilitate single IRB requirements. Through our established quality management programs, we will also assure that network studies are performed in a manner which adhere to good clinical practice. The Duke NCC will provide data management and statistical support for network studies. Duke will build and host project specific REDCap databases from which information can be readily exported to provide project updates through dashboards. Data exports will also be utilized to create reports, presentations and manuscripts to disseminate information regarding the current effectiveness of the respiratory virus vaccine being evaluated given the circulating virus strains or variants.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5150", "attributes": { "award_id": "0908073", "title": "Student Travel Support for IEEE INFOCOM 2009", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "Networking Technology and Syst" ], "program_reference_codes": [], "program_officials": [], "start_date": "2009-03-01", "end_date": "2010-02-28", "award_amount": 25000, "principal_investigator": { "id": 18310, "first_name": "Liang", "last_name": "Cheng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1363, "ror": "", "name": "Institute of Electrical & Electronics Engineers, Inc.", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1363, "ror": "", "name": "Institute of Electrical & Electronics Engineers, Inc.", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "The 2009 IEEE INFOCOM Conference on Computer Communications will be held in Rio de Janeiro, Brazil from April 19 to April 25, 2009. This preeminent technical conference is a primary venue for presenting new research results in the area of computer communications, and is widely attended by researchers and practitioners in the field. Attending conferences such as INFOCOM is of great importance for the development of graduate students. Participants have the opportunity to present their work, attend panel and keynote sessions, and interact with hundreds of others performing leading-edge research in the field. This award provides funds to support approximately sixteen graduate students in the United States to attend this premiere conference. The travel awards will target graduate students, in particular, women and under-represented minority students, since attending conferences is an important part of their educational experience, and they often have limited travel funds. \n\nThe intellectual merit of the proposal resides in encouraging and supporting graduate student attendance to INFOCOM 2009, which will continue the tradition of the previous INFOCOM conferences as a premier venue for bringing together academia, industry, and government to share newest developments in communications. Besides technical paper presentations, the conference offers a wide range of technical activities including workshops and tutorials. \n\nIn terms of its broader impact, this proposal aims at providing graduate students conducting research in the field of communications with the opportunity to attend the INFOCOM 2009, one of the main technical conferences in the field. Attending such high-caliber technical venues is extremely valuable for future researchers. Not only they will be exposed to the state-of-the-art in the field, but also they will have the opportunity to interact with peers from institutions worldwide, meet with leading researchers, and take part in discussions that are likely to shape the future of the field (e.g., in terms of technology, standards, etc.).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10607", "attributes": { "award_id": "75N92022D00013-P00002-759202200001-1", "title": "NIBIB, INNOVATION FUNNEL FOR MATERNAL HEALTH -RADx", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-01", "end_date": "2024-02-29", "award_amount": 338000, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "NICHD, in partnership with the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the NIH Office of the Director, aims to leverage the RADx Tech program’s innovation funnel design—which was used by NIBIB to speed the development, commercialization and implementation of COVID-19 testing technologies—to accelerate the development of diagnostic devices, wearables, or other remote sensing technologies that can reduce SMM/MM for individuals residing in maternity care deserts during the first year of the postpartum period (namely, from day of delivery or end of pregnancy). The innovation funnel approach uses stage-gated, milestone-based award payments to compress the customary technology development timeline. this is accomplished by employing, in parallel, expert teams to address scientific/technical, regulatory, clinical, and commercialization requirements to validate, de-risk, scale up, manufacture, and deploy novel tests through seamless pipeline. Successful outputs from this Challenge may include technologies such as wearable devices, smartphone-enabled diagnostic tools, integrated sensor technologies, and diagnostic devices or tests for use at-home or at the point-of-care (POC). Solutions generated by innovators shall allow continuity of monitoring when access to care providers is limited and extend diagnostic and monitoring capabilities to support timely return to maternity care when necessary. Priority conditions for prediction, detection, diagnosis, and monitoring during the postpartum period may include cardiovascular diseases (such as cardiomyopathies), hemorrhage, sepsis, and mental health conditions (such as postpartum depression), which are recognized as associated with high rates of severe morbidity and mortality during the first year after delivery or end of pregnancy.", "keywords": [ "Address", "Award", "COVID-19 testing", "Cardiomyopathies", "Cardiovascular Diseases", "Caring", "Cellular Phone", "Clinical", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic Equipment", "Diagnostic tests", "Health Services Accessibility", "Hemorrhage", "Home", "Individual", "Maternal Health", "Maternal Health Services", "Maternal Mortality", "Mental Health", "Monitor", "Morbidity - disease rate", "National Institute of Biomedical Imaging and Bioengineering", "National Institute of Child Health and Human Development", "Output", "Postpartum Depression", "Postpartum Period", "Pregnancy", "Pregnancy Outcome", "Prize", "Publications", "Publishing", "RADx", "RADx Tech", "Risk", "Sepsis", "Speed", "Technology", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Vision", "base", "care providers", "commercialization", "design", "diagnostic technologies", "diagnostic tool", "innovation", "mortality", "novel", "payment", "point of care", "programs", "remote sensing", "scale up", "sensor technology", "severe maternal morbidity", "technology development", "wearable device" ], "approved": true } }, { "type": "Grant", "id": "10687", "attributes": { "award_id": "1R43GH002390-01A1", "title": "Pan-COVID Therapeutic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-29", "award_amount": 275766, "principal_investigator": { "id": 26741, "first_name": "JAMES W", "last_name": "LARRICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26742, "first_name": "Bo", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1958, "ror": "", "name": "LARIX BIOSCIENCE, LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pan-COVID Therapeutic Abstract Severe COVID-19 remains as an urgent unmet clinical need for unvaccinated people, particularly as the SARS- CoV-2 delta and omicron variants spread globally. Despite the rapid deployment of effective vaccines, a large percentage of Americans are not fully vaccinated. About 15% of COVID-19 patients require hospitalization with 5% requiring intensive care, among whom nearly half of patients succumb to the disease without an effective therapeutic option. Because angiotensin-converting enzyme 2 (ACE2) is the cell surface receptor of the SARS- CoV-2 spike (S) glycoprotein for cell entry, soluble ACE2 has been used as a decoy receptor to inhibit SARS- CoV-2 infection in vitro and in vivo. However, the affinity of the wild type human ACE2 is not high enough (tens of nM) to warrant therapeutic development. We have generated a high affinity ACE2 (>100-fold). This engineered ACE2 will be effective against all variants, including delta. Fusion of this engineered ACE2 to a human immunoglobulin Fc region is expected to result in superior pharmacokinetics, as Fc will confer a long circulating half-life and the ability to be delivered to airway mucosal surfaces, the primary site of SARS-CoV-2 infection. Unlike anti-SARS-CoV-2 antibodies, the ACE2-Fc decoy fusion protein will not subject the virus to selection for neutralization escape mutants, as any mutation that decreases binding to the decoy will reduce binding to the native receptor, resulting in an attenuated virus. Our engineered ACE2 maintains the peptidase activity that decreases angiotensin II (Ang II) concentration to alleviate AGTR1/AGTR2-mediated vasoconstriction that exacerbates the acute respiratory distress. The active ACE2-Fc will address the underlining pathogenesis of severe COVID-19 in addition to blocking the viral entry, and provides superior efficacy versus neutralizing antibodies. During this Phase 1 project, we will engineer an active ACE2 with >100-fold affinity improvement to the SARS-CoV-2 spike protein, and fuse it to a human Fc. The resulting decoy fusion protein will inhibit viral binding to its receptor ACE2 as well as locally target the renin–angiotensin system (RAS) to attenuate severe respiratory distress. The outcome of this work will be a novel best-in-class therapy for SARS-CoV-2 and potentially other viral acute respiratory distress syndromes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10655", "attributes": { "award_id": "1U54CA272205-01", "title": "University of Maryland First Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 70373, "principal_investigator": { "id": 26713, "first_name": "Marey R.", "last_name": "Shriver", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "SPECIFIC AIMS African American/Black, Hispanic/Latinx, American Indian, and Alaska Native individuals make up 34% of the population, however they are underrepresented in the biomedical sciences. Underrepresented minorities (URM) make up 15% of PhD graduates and representation further along the pipeline in academia shows further attrition with URMs comprising only 9% of Assistant Professor and 4% of tenured faculty positions. Lastly, URM scientists receive only 6% of NIH research grants which are a necessity for establishing and maintaining a successful research career. The inability to maintain a diverse pool of faculty who conduct biomedical and health related research has wide spread implications. Increasing representation within research institutions will allow academic medicine to meet the needs of a diverse nation and address persistent health inequities and disparities, such as those illustrated by the COVID-19 pandemic. To address the critical gap of underrepresentation, institutional strategies must establish equitable and inclusive recruitment and faculty development that directly address existing barriers to this population. The University of Maryland School of Medicine (UMSOM) and the University of Maryland Baltimore County (UMBC) have longstanding individual and collaborative efforts to increase diversity, equity, and inclusion in the biomedical sciences, with programs supporting trainees from middle school to graduate and medical school training. Collectively UMSOM & UMBC pipeline programs and partnerships stemming from these programs have increased the recruitment of UR students and enhanced trainee diversity at all levels; however, recruitment and retention of faculty from underrepresented groups signifies a key gap in this trajectory. Currently, at UMSOM and UMBC URMs make up only 5.3% and 12% of total tenure track faculty, respectively. URM in the biomedical sciences have expressed low representation leads to social and professional isolation. Lack of critical mass of minority faculty, coordinated programs and resources to support retention and promotion, and senior leader who serve as diversity champions have been identified as key barriers to the recruitment, retention, and promotion of URM faculty. To address existing barriers to URM faculty retention and promotion we will build off prior experience from UMBC’s nationally renowned Meyerhoff Scholars Program. The success of students within the Meyerhoff Scholars Program has been attributed to addressing 4 critical factors: academic and social integration, knowledge and skill development, support and motivation, and monitoring and advising. The overall goal of the faculty development core is to transform our faculty development approach through adaptation of the Meyerhoff model using coordinated programs and resources to: 1) support the development, retention, and promotion of URM faculty, 2) create a network of senior leaders who serve as diversity champions to sustain inclusion and equity and, 3) over the long term increase the critical mass of URM faculty within the University of Maryland. Towards this goal, the specific aims of the faculty development core are: • To ensure the University of Maryland (UM) FIRST faculty cohorts achieve academic & social Integration. We will utilize existing campus networks and events, combined with individual support for integration, to ensure UM FIRST faculty are included within the fabric of their academic department and institution. In addition, a pilot grant program will encourage academic integration through the formation of new collaborations between UM FIRST and UMSOM and UMBC investigators. • To use monitoring & advising of UM FIRST faculty cohort progress to support long term success. We will combine individual development plans, mentoring committees, and administrative support to provide continual monitoring and support for UM FIRST faculty career progression. • To ensure UM FIRST faculty develop skills & knowledge in scientific writing, grant writing, and scientific management, leadership, and teaching. UM FIRST faculty will participate in a pre-defined curriculum, the FIRST Curriculum, that will focus on developing the skills and knowledge essential for an independent research career, including the required milestones to achieve promotion and tenure. Informed by their IDP and mentoring committee, UM FIRST faculty will select the most appropriate training based on their current needs in each of the following focus areas: 1) scientific writing; 2) grant writing; and 3) scientific management, leadership, and teaching. • To provide support & motivation to the UM FIRST faculty cohort through peer-mentoring and individual coaching. UM FIRST faculty will participate in peer mentoring groups and receive individual coaching to receive support while pursuing their professional and research goals. By adapting the Meyerhoff model for faculty development we will implement a scalable model to increase coordinated programs and resources to support retention and promotion of URM and create a network of senior leaders who serve as diversity champions. The success of the UM FIRST program is central to the mission of both institutions and a key priority to establish a critical mass of diverse faculty while continuing to enhance equity and inclusion, specifically in the recruitment, retention, and promotion of URM faculty on both campuses.", "keywords": [ "Academia", "Address", "African American", "Alaska Native", "American Indians", "Area", "Baltimore", "Biomedical Research", "Black American", "COVID-19 pandemic", "Cancer Biology", "Collaborations", "Communicable Diseases", "County", "Development", "Development Plans", "Doctor of Philosophy", "Educational Curriculum", "Educational process of instructing", "Engineering", "Ensure", "Event", "Faculty", "Goals", "Grant", "Health", "Hispanic", "Immunology", "Individual", "Inosine Diphosphate", "Institution", "Joints", "Knowledge", "Latinx", "Leadership", "Maryland", "Medicine", "Mentors", "Microbiology", "Minority", "Mission", "Modeling", "Monitor", "Motivation", "NCI Scholars Program", "Neurosciences", "Population", "Positioning Attribute", "Research", "Research Personnel", "Research Project Grants", "Resources", "STEM program", "Science", "Students", "Teacher Professional Development", "Technology", "Textiles", "Training", "Underrepresented Minority", "Underrepresented Populations", "Underrepresented Students", "United States National Institutes of Health", "Universities", "Writing", "base", "career", "cohort", "diversity and equity", "experience", "health disparity", "health inequalities", "junior high school", "medical schools", "member", "minority scientist", "peer coaching", "professor", "programs", "recruit", "skill acquisition", "skills", "social", "social integration", "stem", "success", "tenure track", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "10575", "attributes": { "award_id": "1R43GH002389-01A1", "title": "Rapid COVID-19 Mutation Discrimination Test for Global SARS-CoV-2 Variant Surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-31", "award_amount": 275766, "principal_investigator": { "id": 26597, "first_name": "Janet L", "last_name": "Huie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1947, "ror": "", "name": "JAN BIOTECH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Public Health Problem. Covid-19 variant tracking and prevalence is greatly hindered by the lack of quick, high- throughput methods for variant detection. Covid-19 genetic variants are a current and ongoing concern, due to greater transmissibility, morbidity and potential resistance to immunity provided by vaccines. Successful surveillance will likely require full coverage: 100% of people tested (not an extrapolation of sparse or region- specific data). Jan Biotech’s proposed assay quickly detects both known variants and new variants (by detecting unknown sequences through negative results and indicating the need for sequencing) and the probes are easily adapted to detect newly emerging variants of concern and interest. The assay will allow remote and low resource area hospitals and medical centers to quickly and fully assess their community’s SARS-CoV-2 variant index for real-time, evidence-based health mandates. This is both an urgent and very likely a long term need as new variants emerge. Issues with Current Solutions & How Product Meets Unmet Needs. RT-PCR Covid-19 tests provide only a positive or negative result and do not identify genetic variants. Rapid antibody tests for Covid-19 also do not reveal variants. DNA Sequencing of the Covid-19 genome is challenging. The genome is almost 30,000 nucleotides in length and combinations of mutations in different areas of the genome are functional and identifying features of Covid-19 variants. High-throughput RNAseq methods for next-generation sequencing (NGS) require RNA purification, RT-PCR RNAseq library preparation and time-consumptive sequencing and genome assembly. Covid-19 sequencing in any format for identification of variants has not yet been CLIA- or FDA-approved. RT-qPCR assays mined for variant data rely on altered Ct curves, which are nonspecific and can be caused by variations in the assay run. The proposed rapid Covid-19 variant detection and discrimination test, performed in a multiwell plate, is variant-specific and high-throughput. Summary of Approach. We will create RNAamp oligonucleotide-templated photoreduction probe sets specific to the current most prevalent and clinically-significant Covid-19 RNA variants. We will multiplex the Covid-19 variant discrimination RNAamp tests, using different profluorophores for each target and evaluate sensitivity and reliability of multiplex results using negative human saliva samples spiked with multiple Covid-19 variant RNAs. Human samples will be used to assess commercial potential of the multiplexed Covid-19 variant RNAamp test. Covid-19 negative samples will serve as negative controls and the same negative samples spiked with Covid- 19 variant control RNAs will serve as positive controls for each variant test to achieve a statistical correlation of >0.9 with comparison assays as the metric of success. Collaborators and Unique Resources. Jan Biotech, Inc., with expertise in molecular diagnostic development, will obtain human Covid-19 positive and negative test samples from the University of Rochester Medical Center, and, as needed, from Precision for Medicine and BocaBiolistics. Specific Aims Specific Aim 1: Develop multiplexed variant discrimination RNAamp test for Covid-19 strain detection Objective 1.1: Develop and test RNAamp probe sets to differentiate Covid-19 variants of concern. Objective 1.2: Multiplex and test the Covid-19 variant discrimination RNAamp tests. Specific Aim 2: Evaluate variant discrimination RNAamp test on Covid-19 human samples Objective 2.1: Test human samples to assess commercial potential of multiplexed Covid-19 variant RNAamp. Objective 2.2: Statistical determination of assay limit of detection and specificity for each Covid-19 variant will evaluate the utility of the rapid Covid-19 variant discrimination test, including its application to pooled samples. The end result of the project will be a multiplexed Covid-19 variant discrimination test and computational software providing proof-of-concept for Phase II preclinical and clinical evaluation leading towards CLIA or 510(k) approval, clinical trials and commercialization.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1405, "count": 14046 } } }